Search

Your search keyword '"Vincenzi, Brenda"' showing total 29 results
Start Over Author "Vincenzi, Brenda"
29 results on '"Vincenzi, Brenda"'

1. Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS).

Author

Tjeertes, Jorrit, Bacino, Carlos, Bichell, Terry, Bustamante, Mariana, Crean, Rebecca, Jeste, Shafali, Komorowski, Robert, Krishnan, Michelle, Miller, Meghan, Nobbs, David, Ochoa-Lubinoff, Cesar, Parkerson, Kimberly, Rotenberg, Alexander, Sadhwani, Anjali, Shen, Mark, Squassante, Lisa, Tan, Wen-Hann, Vincenzi, Brenda, Wheeler, Anne, Hipp, Joerg, Berry-Kravis, Elizabeth, and Bird, Lynne

Subjects
Angelman syndrome, Clinical outcome assessments, Clinical trials, Digital health technology, EEG, Endpoint development, Natural history, Sleep, UBE3A, Humans, Angelman Syndrome, Prospective Studies, Pandemics, COVID-19, Electroencephalography
Abstract

BACKGROUND: Angelman syndrome (AS) is a rare neurodevelopmental disorder characterized by the absence of a functional UBE3A gene, which causes developmental, behavioral, and medical challenges. While currently untreatable, comprehensive data could help identify appropriate endpoints assessing meaningful improvements in clinical trials. Herein are reported the results from the FREESIAS study assessing the feasibility and utility of in-clinic and at-home measures of key AS symptoms. METHODS: Fifty-five individuals with AS (aged

Published
2023

6. Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)

Author

Tjeertes, Jorrit, primary, Bacino, Carlos A., additional, Bichell, Terry Jo, additional, Bird, Lynne M., additional, Bustamante, Mariana, additional, Crean, Rebecca, additional, Jeste, Shafali, additional, Komorowski, Robert W., additional, Krishnan, Michelle L., additional, Miller, Meghan T., additional, Nobbs, David, additional, Ochoa-Lubinoff, Cesar, additional, Parkerson, Kimberly A., additional, Rotenberg, Alexander, additional, Sadhwani, Anjali, additional, Shen, Mark D., additional, Squassante, Lisa, additional, Tan, Wen-Hann, additional, Vincenzi, Brenda, additional, Wheeler, Anne C., additional, Hipp, Joerg F., additional, and Berry-Kravis, Elizabeth, additional

Published
2023
Full Text
View/download PDF

10. Does a physician's attitude toward a patient with mental illness affect clinical management of diabetes? Results from a mixed-method study

Author

Welch, Lisa C., Litman, Heather J., Borba, Christina P.C., Vincenzi, Brenda, and Henderson, David C.

Subjects
Chronic diseases -- Research -- Methods -- Health aspects, Diabetes -- Research -- Methods -- Health aspects, Mentally ill -- Methods -- Health aspects, Mental illness -- Research -- Methods -- Health aspects, Business, Health care industry
Abstract

Objective. To determine whether physician's attitudes toward patients with comorbid mental illness affect management of a chronic disease. Data Source. A total of 256 primary care physicians interviewed in 2010. Study Design. This randomized factorial experiment entailed physicians observing video vignettes of patient-actors with poorly controlled diabetes. Patients were balanced across age, gender, race, and comorbidity (schizophrenia with bizarre or normal affect, depression, eczema). Data Collection. Physicians completed structured and semistructured interviews plus chart notes about clinical management and attitudes. Principal Findings. Physicians reported more negative attitudes for patients with schizophrenia with bizarre affect (SBA). There were few differences in clinical decisions measured quantitatively or in charting, but qualitative data revealed less trust of patients with SBA as reporters, with more reliance on sources other than engaging the patient in care. Physicians often alerted colleagues about SBA, thereby shaping expectations before interactions occurred. Conclusions. Results are consistent with common stereotypes about people with serious mental illness. Vignettes did not include intentional indication of unreliable reporting or danger. Reducing health care disparities requires attention to subtle aspects of managing patients--particularly those with atypical affect--as seemingly slight differences could engender disparate patient experiences over time. Key Words. Clinical decision making, stigma, mental illness, diabetes, Although disparities in health and health care often are associated with demographic characteristics such as race and ethnicity, people with mental illness also experience systematic obstacles to optimal health (DHHS [...]

Published
2015
Full Text
View/download PDF

17. Colaboradores

Author

Abernethy, Robert S., III, Abrams, Annah N., Alonso, Anne, Alpay, Menekse, Alpert, Jonathan E., Baek, Ji Hyun, Baer, Lee, Beach, Scott R., Beck, B.J., Benedek, David M., Beresin, Eugene V., Bianchi, Matt, Biederman, Joseph, Blais, Mark A., Borba, Christina P.C., Bostic, Jeff Q., Brendel, Rebecca Weintraub, Brennan, Megan Moore, Brezing, Christina A., Brown, Hannah E., Bui, Eric, Bush, George, Buxton, David C., Calkins, Amanda W., Camprodon, Joan A., Caplan, Jason P., Carter, Christopher, Cassano, Paolo, Cassem, Ned H., Chang, Trina E., Chanoff, Marni, Cohen, Lee S., Cremens, M. Cornelia, Dekel, Sharon, Delong, Hannah, Derenne, Jennifer L., Dickerson, Bradford C., Donovan, Abigail L., Dougherty, Darin D., Ducharme, Simon, Ebert, Daniel H., Eddy, Kamryn T., Edersheim, Judith G., Eyler, A. Evan, Falk, William E., Fava, Maurizio, Fernandez-Robles, Carlos, Finn, Christine T., Fishel, Anne K., Flaherty, Alice W., Freudenreich, Oliver, Fricchione, Gregory L., Gatchel, Jennifer R., Georgiopoulos, Anna M., Gerken, Adrienne T., Gerstenblith, Ted Avi, Gilbertson, Mark W., Goff, Donald C., Gordon, Christopher, Gould, Cathleen M., Greenberg, Donna B., Greer, David M., Gross, Anne F., Groves, James E., Hazen, Eric P., Heffernan, Sean P., Henderson, David C., Herman, John B., Hidalgo, José A., Hirdes, John P., Hogan, Charlotte, Holt, Daphne J., Hopwood, Christopher J., Hsin, Honor, Huffman, Jeff C., Hutner, Lucy A. Epstein, Ivkovic, Ana, Jenike, Michael A., Julian, John N., Katon, Jesse M., Kaur, Navneet, Kelly, John F., Keuroghlian, Alex S., Keuthen, Nancy J., Khoshbin, Shahram, Kinrys, Gustavo, Klibanski, Anne, Kontos, Nicholas, Kutner, Lawrence, Lafleur, Daniel, Lagomasino, Isabel T., LeBeau, Richard T., Leveroni, Catherine, Maytal, Guy, McKeon, Jeanne, Mickley, Diane W., Milosavljevic, Nada, Mischoulon, David, Mollica, Richard F., Muriel, Anna C., Murray, Evan D., Murray, George B., Murray, Helen B., Nejad, Shamim H., Nicolson, Stephen E., Nierenberg, Andrew A., Nonacs, Ruta M., O’Brien, Kevin M., O’Keefe, Sheila M., Olatunji, Bunmi O., Olson, Cheryl K., Öngür, Dost, Oppenheim, Claire E., Orr, Scott P., Ostacher, Michael J., Østergaard, Søren Dinesen, Otto, Michael W., Papakostas, George I., Perlis, Roy H., Pirl, William F., Pitman, Roger K., Pollack, Mark H., Pollak, Lauren Norton, Powell, Alicia D., Prager, Laura M., Price, Bruce H., Prince, Jefferson B., Querques, John, Rabinowitz, Terry, Rauch, Scott L., Reese, Hannah E., Renner, John A., Ritchie, Elspeth Cameron, Rivas-Vazquez, Rafael A., Roffman, Joshua L., Rosenbaum, Jerrold F., Rosenfield, Elizabeth, Rosenquist, J. Niels, Rubin, David Harris, Rundell, James R., Sanders, Kathy M., Schlozman, Steven C., Schouten, Ronald, Shafer, Linda C., Sherman, Janet Cohen, Shtasel, Derri, Simon, Naomi M., Sinclair, Samuel Justin, Smallwood, Patrick, Smith, Felicia A., Smoller, Jordan W., Spencer, Thomas J., Sprich, Susan E., Stakes, John W., Stern, Theodore A., Stewart, S. Evelyn, Stewart, Samantha Andrien, Stewart, Thomas D., Surman, Owen S., Tanev, Kaloyan S., Tayeb, Haythum O., Taylor, Charles T., Taylor, John B., Thomas, Jennifer J., Tompkins, Kathryn J., Traeger, Lara, Trinh, Nhi-Ha, Ulman, Kathleen Hubbs, Vasconcelos e, Débora, Viguera, Adele C., Vincenzi, Brenda, Viron, Mark, Wang, Betty, Ward, E. Nalan, Wasan, Ajay D., Weilburg, Jeffrey B., Weisholtz, Daniel, Weissman, Anna R., Welch, Charles A., Wilens, Timothy E., Wilhelm, Sabine, Wood, Nellie E., Wright, Christopher I., Wynn, Gary H., Yeung, Albert S., and Zulauf, Courtney

Published
2018
Full Text
View/download PDF

19. List of Contributors

Author

Abernethy, Robert S., III, Abrams, Annah N., Alonso, Anne, Alpay, Menekse, Alpert, Jonathan E., Baek, Ji Hyun, Baer, Lee, Beach, Scott R., Beck, BJ, Benedek, David M., Beresin, Eugene V., Bianchi, Matt, Biederman, Joseph, Blais, Mark A., Borba, Christina P.C., Bostic, Jeff Q., Brendel, Rebecca Weintraub, Brennan, Megan Moore, Brezing, Christina A., Brown, Hannah E., Bui, Eric, Bush, George, Buxton, David C., Calkins, Amanda W., Camprodon, Joan A., Caplan, Jason P., Carter, Christopher, Cassano, Paolo, Cassem, Ned H., Chang, Trina E., Chanoff, Marni, Cohen, Lee S., Cremens, M. Cornelia, Dekel, Sharon, Delong, Hannah, Derenne, Jennifer L., Dickerson, Bradford C., Donovan, Abigail L., Dougherty, Darin D., Ducharme, Simon, Ebert, Daniel H., Eddy, Kamryn T., Edersheim, Judith G., Eyler, A. Evan, Falk, William E., Fava, Maurizio, Fernandez-Robles, Carlos, Finn, Christine T., Fishel, Anne K., Flaherty, Alice W., Freudenreich, Oliver, Fricchione, Gregory L., Gatchel, Jennifer R., Georgiopoulos, Anna M., Gerken, Adrienne T., Gerstenblith, Ted Avi, Gilbertson, Mark W., Goff, Donald C., Gordon, Christopher, Gould, Cathleen M., Greenberg, Donna B., Greer, David M., Gross, Anne F., Groves, James E., Hazen, Eric P., Heffernan, Sean P., Henderson, David C., Herman, John B., Hidalgo, José A., Hirdes, John P., Hogan, Charlotte, Holt, Daphne J., Hopwood, Christopher J., Hsin, Honor, Huffman, Jeff C., Epstein, Lucy A., Ivkovic, Ana, Jenike, Michael A., Julian, John N., Katon, Jesse M., Kaur, Navneet, Kelly, John F., Keuroghlian, Alex S., Keuthen, Nancy J., Khoshbin, Shahram, Kinrys, Gustavo, Klibanski, Anne, Kontos, Nicholas, Kutner, Lawrence, Lafleur, Daniel, Lagomasino, Isabel T., LeBeau, Richard T., Leveroni, Catherine, Maytal, Guy, McKeon, Jeanne, Mickley, Diane W., Milosavljevic, Nada, Mischoulon, David, Mollica, Richard F., Muriel, Anna C., Murray, Evan D., Murray, George B., Murray, Helen B., Nejad, Shamim H., Nicolson, Stephen E., Nierenberg, Andrew A., Nonacs, Ruta M., O'Brien, Kevin M., O'Keefe, Sheila M., Olatunji, Bunmi O., Olson, Cheryl K., Öngür, Dost, Oppenheim, Claire E., Orr, Scott P., Ostacher, Michael J., Dinesen, Søren, Otto, Michael W., Papakostas, George I., Perlis, Roy H., Pirl, William F., Pitman, Roger K., Pollack, Mark H., Pollak, Lauren Norton, Powell, Alicia D., Prager, Laura M., Price, Bruce H., Prince, Jefferson B., Querques, John, Rabinowitz, Terry, Rauch, Scott L., Reese, Hannah E., Renner, John A., Jr., Ritchie, Elspeth Cameron, Rivas-Vazquez, Rafael A., Roffman, Joshua L., Rosenbaum, Jerrold F., Rosenfield, Elizabeth, Rosenquist, J. Niels, Rubin, David Harris, Rundell, James R., Sanders, Kathy M., Schlozman, Steven C., Schouten, Ronald, Shafer, Linda C., Sherman, Janet Cohen, Shtasel, Derri, Simon, Naomi M., Sinclair, Samuel Justin, Smallwood, Patrick, Smith, Felicia A., Smoller, Jordan W., Spencer, Thomas J., Sprich, Susan E., Stakes, John W., Stern, Theodore A., Stewart, S. Evelyn, Stewart, Samantha Andrien, Stewart, Thomas D., Surman, Owen S., Tanev, Kaloyan S., Tayeb, Haythum O., Taylor, Charles T., Taylor, John B., Thomas, Jennifer J., Tompkins, Kathryn J., Traeger, Lara, Trinh, Nhi-Ha, Ulman, Kathleen Hubbs, Vasconcelos e Sá, Débora, Viguera, Adele C., Vincenzi, Brenda, Viron, Mark, Wang, Betty, Ward, E. Nalan, Wasan, Ajay D., Weilburg, Jeffrey B., Weisholtz, Daniel, Weissman, Anna R., Welch, Charles A., Wilens, Timothy E., Wilhelm, Sabine, Wood, Nellie E., Wright, Christopher I., Wynn, Gary H., Yeung, Albert S., and Zulauf, Courtney

Published
2016
Full Text
View/download PDF

27. Open-label pilot study on vitamin D3supplementation for antipsychotic-associated metabolic anomalies

Author

Thakurathi, Neelam, Stock, Shannon, Oppenheim, Claire E., Borba, Christina P.C., Vincenzi, Brenda, Seidman, Larry J., Stone, William S., and Henderson, David C.

Abstract

Previous studies have linked vitamin D deficiency to hypertension, dyslipidemia, diabetes mellitus, and cardiovascular disease. The aim of this study was to investigate the short-term effects of vitamin D3supplementation on weight and glucose and lipid metabolism in antipsychotic-treated patients. A total of 19 schizophrenic or schizoaffective patients (BMI>27 kgm2) taking atypical antipsychotics were recruited and dispensed a 2000 IU daily dose of vitamin D3. On comparing baseline with week 8 (study end) results, we found a statistically significant increase in vitamin D3and total vitamin D levels but no statistically significant changes in weight, glucose, or lipids measurements. Patients whose vitamin D3level at week 8 was 30 ngml or more achieved a significantly greater decrease in total cholesterol levels compared with those whose week 8 vitamin D3measurement was less than 30 ngml. These results suggest that a randomized trial with a longer follow-up period would be helpful in further evaluating the effects of vitamin D3on weight, lipid metabolism, and on components of metabolic syndrome in antipsychotic-treated patients.

Published
2013
Full Text
View/download PDF

28. Assessing the prospect of donepezilin improving cognitive impairment in patients with schizophrenia

Author

Thakurathi, Neelam, Vincenzi, Brenda, and Henderson, David C

Abstract

Introduction:Even though cognitive impairment is manifested in almost all patients with schizophrenia, the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) study showed no significant difference between first- and second-generation psychotropic drugs in improving cognitive abilities. Discovering new drugs that can improve impaired cognition, thus, is an attractive treatment target for patients with schizophrenia.Areas covered:This article briefly reviews about donepezil, a highly selective (IC50 6.7 nM) centrally acting reversible acetylcholinesterase inhibitor that has been approved by FDA for treating cognitive deficit states such as in Alzheimer's disease and its uses in clinical trials for the treatment of schizophrenia. The literature search included PubMed and Cochrane library with the following words: donepezil, schizophrenia and cognitive impairments.Expert opinion:The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option. While longer randomized controlled trials, increase dosage and selected groups of patients at different stage of cognitive impairment may provide a better understanding of the potential for this drug in addressing cognitive deficits, results to date have not been encouraging.

Published
2013
Full Text
View/download PDF

29. Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.

Author

Thakurathi N, Vincenzi B, and Henderson DC

Subjects
Binding Sites, Cholinesterase Inhibitors administration & dosage, Cholinesterase Inhibitors chemistry, Cholinesterase Inhibitors pharmacology, Clinical Trials as Topic, Cognition Disorders psychology, Donepezil, Humans, Indans administration & dosage, Indans chemistry, Indans pharmacology, Models, Molecular, Molecular Structure, Piperidines administration & dosage, Piperidines chemistry, Piperidines pharmacology, Schizophrenia complications, Schizophrenic Psychology, Treatment Outcome, Cholinesterase Inhibitors therapeutic use, Cognition Disorders drug therapy, Indans therapeutic use, Piperidines therapeutic use, Schizophrenia drug therapy
Abstract

Introduction: Even though cognitive impairment is manifested in almost all patients with schizophrenia, the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) study showed no significant difference between first- and second-generation psychotropic drugs in improving cognitive abilities. Discovering new drugs that can improve impaired cognition, thus, is an attractive treatment target for patients with schizophrenia., Areas Covered: This article briefly reviews about donepezil, a highly selective (IC(50) = 6.7 nM) centrally acting reversible acetylcholinesterase inhibitor that has been approved by FDA for treating cognitive deficit states such as in Alzheimer's disease and its uses in clinical trials for the treatment of schizophrenia. The literature search included PubMed and Cochrane library with the following words: donepezil, schizophrenia and cognitive impairments., Expert Opinion: The results of several clinical trials utilizing donepezil as an adjunct to second-generation antipsychotic drugs targeting cognitive deficits in schizophrenia subjects have been disappointing and would not lead clinicians to consider this as a potential treatment option. While longer randomized controlled trials, increase dosage and selected groups of patients at different stage of cognitive impairment may provide a better understanding of the potential for this drug in addressing cognitive deficits, results to date have not been encouraging.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results